Sikkim Journal

Epithelial Ovarian Cancer Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Epithelial Ovarian Cancer Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

February 10
20:56 2021
Epithelial Ovarian Cancer Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Epithelial Ovarian Cancer Market

(Albany, US) DelveInsight has launched a new report on Epithelial Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2030.


DelveInsight’s ” Epithelial Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Epithelial Ovarian Cancer, historical and forecasted epidemiology as well as the Epithelial Ovarian Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some of Epithelial Ovarian Cancer Facts:

  • The rate of new cases of ovarian cancer was 11.2 per 100,000 women per year. The death rate was 6.7 per 100,000 women per year.
  • Epithelial ovarian carcinomas (EOC) account for ~90% of all ovarian malignancies.
  • In 2020 more than 300 000 new cases of EOC are expected worldwide, with more than 190 000 deaths.
  • Ovarian cancer is a disease that affects women. This cancer mainly develops in older women.


Request for Free Sample Report:


Scope of Epithelial Ovarian Cancer Report:

  • The report covers the descriptive overview of Epithelial Ovarian Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Epithelial Ovarian Cancer epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Epithelial Ovarian Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Epithelial Ovarian Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epithelial Ovarian Cancer market


Request for Free Sample Report:


Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. It is one of the most common gynecologic cancers, and one of the leading causes of cancer-associated female mortality in the world. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

Epithelial ovarian tumors develop from the cells that cover the outer surface of the ovary. Most epithelial ovarian tumors are benign. There are several types of benign epithelial tumors, including serous adenomas, mucinous adenomas, and Brenner tumors. Cancerous epithelial tumors are carcinomas – meaning they begin in the tissue that lines the ovaries.

There are some ovarian epithelial tumors whose appearance under the microscope does not clearly identify them as cancerous and they are called borderline tumors or tumors of low malignant potential (LMP tumors).

Epithelial cancer of the ovary is thought to derive from malignant transformation of the epithelium of the ovarian surface, peritoneum, or fallopian tube. The exact molecular transformation events causing EOC are not known. Studies have shown that epigenetic phenomenon may also play a role. Mutations of the oncogenes HER2, C-myc, K-ras, Akt, and the tumor suppressor gene p53 have been observed.

The clinical presentation of EOC can either be acute or subacute. Acute cases present with conditions such as pleural effusion, small bowel obstruction and venous thromboembolism.

Subacute cases may present with non specific symptoms such as abdominal fullness, bloating, an adnexal mass, vague pelvic or abdominal pain and gastrointestinal symptoms.

During the last decade it has become apparent that EOC encompasses 5 distinct diseases, with different presentations (age of development, distribution of disease), response to chemotherapy, prognosis, molecular features, and site of origin. While these carcinomas share a common site of tumor growth in the ovary, they represent diverse diseases entities. This has driven the move towards more histotype specific management strategies.


Request for Free Sample Report:


Some of Epithelial Ovarian Cancer Companies:

  • Immunogen
  • Celsion Corporation
  • OncoQuest
  • Roche
  • Precigen
  • Ellipses Pharma
  • And Many Others

Epithelial Ovarian Cancer Drugs Covered:

  • Mirvetuximab
  • GEN-1
  • Oregovomab
  • Tecentriq
  • PRGN-3005 UltraCAR-T
  • EP0057
  • And Many Others


Request for Free Sample Report:


Table of Contents:

1. Key Insights

2. Executive Summary of Epithelial Ovarian Cancer

3. Competitive Intelligence Analysis for Epithelial Ovarian Cancer

4. Epithelial Ovarian Cancer: Market Overview at a Glance

5. Epithelial Ovarian Cancer: Disease Background and Overview

6. Patient Journey

7. Epithelial Ovarian Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Epithelial Ovarian Cancer Treatment

11. Marketed Products

12. Emerging Therapies

13. Epithelial Ovarian Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Epithelial Ovarian Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Related Articles